Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Ruxolitinib & COVID-19

Alessandro Gozzetti, MD, PhD, Azienda Ospedaliera Universitaria Senese, Siena, Italy, discusses the use of ruxolitinib, a selective inhibitor of the Janus-associated tyrosine kinases (JAK1 and JAK2), in patients infected with COVID-19. Ruxolitinib was found to be efficacious in terms of reducing ICU admissions. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.